Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
Source ↗
👁 0
💬 0
A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame.
Comments (0)